Brief: FDA Accelerates Approval Of Tofersen

Quanterix

25/04/2023 21:58

April 25 (Reuters) - Quanterix Corp  QTRX.O :
    * FDA ACCELERATED APPROVAL OF TOFERSEN HIGHLIGHTS IMPORTANCE
OF
BLOOD NEUROFILAMENT LIGHT CHAIN AS SURROGATE ENDPOINT IN
NEUROLOGY THERAPEUTIC TRIALS
    * FDA ACCELERATED APPROVAL OF TOFERSEN HIGHLIGHTS IMPORTANCE
OF
BLOOD NEUROFILAMENT LIGHT CHAIN AS SURROGATE ENDPOINT IN
NEUROLOGY THERAPEUTIC TRIALS

Source text for Eikon:  ID:nBw1fjGYma 
Further company coverage:  QTRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))